New Treatments for Vaginal Atrophy & Menopause Symptoms

Introduction

Vaginal atrophy, now more accurately termed genitourinary syndrome of menopause (GSM), affects a majority of postmenopausal women. Characterized by dryness, burning, and urinary incontinence, it stems from a decline in estrogen. New research is expanding the treatment toolkit beyond traditional hormone creams, offering non-hormonal options with distinct mechanisms of action.

Photobiomodulation: Light Therapy Shows Promise for Urinary Symptoms

A placebo-controlled trial from Brazilian researchers provides evidence for a novel non-hormonal treatment. The team, led by Pereira SRDS from Universidade Nove de Julho, tested photobiomodulation (PBM) therapy on 65 postmenopausal women with GSM. Participants received four weekly sessions where an 808 nm laser was applied to eight specific vaginal points for 40 seconds each.

The mechanism is distinct from estrogen replacement. PBM uses specific wavelengths of light to penetrate tissue and be absorbed by cellular components called mitochondria. This absorption boosts the production of adenosine triphosphate (ATP), the fundamental energy currency of the cell. Enhanced ATP gives vaginal and urethral cells more resources to repair themselves, reduce inflammation, and increase local blood flow. This process can thicken the vaginal epithelium and improve tissue elasticity without introducing external hormones.

Results were clear for urinary symptoms. The PBM group showed a significant reduction in urinary loss and better scores on a standard incontinence questionnaire compared to the placebo group. Women also reported subjective improvements in vaginal dryness and burning. However, the study found no significant difference between groups for pelvic pressure or sexual function, indicating the treatment’s effects may be specific to certain symptoms. The protocol’s long-term durability remains to be studied.

A Personalized Framework for Treatment Decisions

How should this new evidence fit into clinical practice? A case-based review by Cyriac J and Sood R from the Mayo Clinic stresses that effective GSM management is inherently personalized. They argue against a linear treatment algorithm, favoring a decision framework that weighs multiple factors.

The first step is a thorough assessment to rule out other conditions that mimic GSM, such as infections or dermatological issues. Treatment choice then depends on symptom severity, the patient’s cancer history (especially breast cancer), personal risk factors for conditions like blood clots, and, importantly, her own preferences and goals. For a woman with mild dryness who prefers non-prescription options, a regimen of regular moisturizers and lubricants may suffice. For another with severe atrophy and urinary pain, low-dose vaginal estrogen might be the most effective first-line therapy.

This personalized approach is particularly relevant for cancer survivors, for whom local estrogen may be contraindicated or cause anxiety. For these patients, non-hormonal options like PBM, vaginal moisturizers containing hyaluronic acid, and probiotics aimed at the vaginal microbiome become critical parts of the plan. The framework treats patient preference not as an afterthought but as a central pillar of care.

Integrating New Options into a Symptom-Specific Plan

The emerging evidence supports building a symptom-targeted treatment plan. For primary symptoms of vaginal dryness and discomfort, the mainstay remains vaginal moisturizers used regularly and lubricants used during intercourse. When these are insufficient, low-dose vaginal estrogen (creams, tablets, or rings) is highly effective and has minimal systemic absorption. Newer agents like the oral medication ospemifene, a selective estrogen receptor modulator, also offer a systemic non-estrogen option for dyspareunia.

For urinary incontinence and urgency, the spectrum of options widens. The PBM trial offers a new, non-invasive in-office procedure. Pelvic floor physical therapy, which strengthens the muscles supporting the bladder and urethra, has strong evidence for stress incontinence. Kegels and electromagnetic stimulation can be part of this therapy. For overactive bladder symptoms, medications like anticholinergics or beta-3 agonists may be considered. Sexual function concerns may involve addressing pain first, then considering therapies like testosterone for menopause for low libido, if appropriate, after a detailed consultation.

Acknowledging limitations is part of integrative care. PBM requires access to specific equipment and multiple clinic visits. Vaginal estrogen, while safe for most, is not suitable for all. The key is open dialogue: a treatment plan may start with one option and incorporate another if response is partial or if new symptoms arise.

Conclusion

Managing GSM is a proactive necessity for long-term health. Research continues to move beyond a one-dimensional approach, validating new tools like photobiomodulation for urinary symptoms and reinforcing the need for personalized care. By matching the treatment mechanism to the individual’s specific symptoms and health profile, clinicians and patients can effectively restore comfort and function.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42060269/
https://pubmed.ncbi.nlm.nih.gov/41892504/